Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
Google ScholarÂ
Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021;79:82–104.
Google ScholarÂ
Warrick JI, Al-Ahmadie H, Berman DM, Black PC, Flaig TW, Höglund M, et al. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility. Am J Surg Pathol. 2024;48:e32–e42.
Google ScholarÂ
Hingorani SR. Epithelial and stromal co-evolution and complicity in pancreatic cancer. Nat Rev Cancer. 2023;23:57–77.
Google ScholarÂ
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–8.
Google ScholarÂ
Wang H, Mei Y, Luo C, Huang Q, Wang Z, Lu GM, et al. Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer. Clin Cancer Res. 2021;27:6265–78.
Google ScholarÂ
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.
Google ScholarÂ
Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene – the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19:23–36.
Google ScholarÂ
Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet. 2008;40:1307–12.
Google ScholarÂ
Ribal MJ, Alcaraz A, Mengual L, Carrio A, Lopez-Guillermo A, Mallofre C, et al. Chromosomal high-polysomies predict tumour progression in T1 transitional cell carcinoma of the bladder. Eur Urol. 2004;45:593–9.
Google ScholarÂ
Kim H, Nguyen NP, Turner K, Wu S, Gujar AD, Luebeck J, et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet. 2020;52:891–7.
Google ScholarÂ
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.
Google ScholarÂ
Ma Z, Li X, Mao Y, Wei C, Huang Z, Li G, et al. Interferon-dependent SLC14A1(+) cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell. 2022;40:1550–65 e7.
Google ScholarÂ
Sardi I, Dal Canto M, Bartoletti R, Guazzelli R, Travaglini F, Montali E. Molecular genetic alterations of c-myc oncogene in superficial and locally advanced bladder cancer. Eur Urol. 1998;33:424–30.
Google ScholarÂ
Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, et al. Direct activation of TERT transcription by c-MYC. Nat Genet. 1999;21:220–4.
Google ScholarÂ
Gomez-Roman N, Grandori C, Eisenman RN, White RJ. Direct activation of RNA polymerase III transcription by c-Myc. Nature. 2003;421:290–4.
Google ScholarÂ
Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W, Tzatsos A. Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. Cancer Cell. 2018;33:512–26 e8.
Google ScholarÂ
Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. 2014;111:3110–5.
Google ScholarÂ
Hovelson DH, Udager AM, McDaniel AS, Grivas P, Palmbos P, Tamura S, et al. Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications. Eur Urol. 2018;74:741–53.
Google ScholarÂ
Robertson AG, Groeneveld CS, Jordan B, Lin X, McLaughlin KA, Das A, et al. Identification of differential tumor subtypes of T1 bladder cancer. Eur Urol. 2020;78:533–7.
Google ScholarÂ
Wang Y, Ju L, Wang G, Qian K, Jin W, Li M, et al. DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC. Nat Commun. 2023;14:2421.
Google ScholarÂ
Li M, Yu J, Ju L, Wang Y, Jin W, Zhang R, et al. USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer. Cell Death Dis. 2024;15:44.
Google ScholarÂ
Ma J, Li L, Ma B, Liu T, Wang Z, Ye Q, et al. MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation. Nat Commun. 2024;15:1871.
Google ScholarÂ
Butler DSC, Cafaro C, Putze J, Wan MLY, Tran TH, Ambite I, et al. A bacterial protease depletes c-MYC and increases survival in mouse models of bladder and colon cancer. Nat Biotechnol. 2021;39:754–64.
Google ScholarÂ
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–56 e25.
Google ScholarÂ
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353–7.
Google ScholarÂ
Liu Z, Jin K, Zeng H, Shao F, Chang Y, Wang Y, et al. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer. Eur J Cancer. 2022;171:133–42.
Google ScholarÂ
Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, et al. Identification and validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2018;24:3069–78.
Google ScholarÂ
Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299–311.
Google ScholarÂ
Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, et al. Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell. 2024;42:2098–112 e4.
Google ScholarÂ
Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–65.
Google ScholarÂ
Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, et al. A Consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420–33.
Google ScholarÂ
Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018;556:463–8.
Google ScholarÂ
Haerinck J, Goossens S, Berx G. The epithelial-mesenchymal plasticity landscape: principles of design and mechanisms of regulation. Nat Rev Genet. 2023;24:590–609.
Google ScholarÂ
Guo CC, Lee S, Lee JG, Chen H, Zaleski M, Choi W, et al. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat Rev Urol. 2024;21:391–405.
Google ScholarÂ
Ueda Y, Kiyonaka S, Selfors LM, Inoue K, Harada H, Doura T, et al. Intratumour oxidative hotspots provide a niche for cancer cell dissemination. Nat Cell Biol. 2025;27:530–43.
Google ScholarÂ
Fiorini E, Malinova A, Schreyer D, Pasini D, Bevere M, Alessio G, et al. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Nature. 2025;640:811–20.
Google ScholarÂ
Thompson EW, Redfern AD, Brabletz S, Berx G, Agarwal V, Ganesh K, et al. EMT and cancer: what clinicians should know. Nat Rev Clin Oncol. 2025;22:711–33.
Google ScholarÂ
Lugli A, Zlobec I, Berger MD, Kirsch R, Nagtegaal ID. Tumour budding in solid cancers. Nat Rev Clin Oncol. 2021;18:101–15.
Google ScholarÂ
Fukumoto K, Kikuchi E, Mikami S, Ogihara K, Matsumoto K, Miyajima A, et al. Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers. Cancer Sci. 2016;107:1338–44.
Google ScholarÂ
Eckstein M, Matek C, Wagner P, Erber R, Buttner-Herold M, Wild PJ, et al. Proposal for a novel histological scoring system as a potential grading approach for muscle-invasive urothelial bladder cancer correlating with disease aggressiveness and patient outcomes. Eur Urol Oncol. 2024;7:128–38.
Google ScholarÂ
Li X, Zou C, Wang C, Chang C, Lin Y, Liang S, et al. Non-invasive tumor budding evaluation and correlation with treatment response in bladder cancer: a multi-center cohort study. Adv Sci. 2025;12:e2416161.
Google ScholarÂ
Garralda E, Beaulieu ME, Moreno V, Casacuberta-Serra S, Martinez-Martin S, Foradada L, et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat Med. 2024;30:762–71.
Google ScholarÂ
